Vote Scores

Home / Companies / Neuren Pharmaceuticals Limited / 27 May 2026

Meeting · year to 30 June 202624 filers reporting

Neuren Pharmaceuticals Limited: meeting of 27 May 2026

Votes reported on Form N-PX, item by item

24 Form N-PX filers reported votes at the Neuren Pharmaceuticals Limited meeting of 27 May 2026. Their records fall into 5 items below, in ballot order: management items first, then proposals from security holders. Each bar shows how the reporting filers split; it is not the result of the meeting.

foragainstabstain, withhold or otheramber tick: the portion cast against management

Items

1

DIRECTOR ELECTIONSIssuer

Director elections

1 nominee; 100.0% of reported votes for; no filer withheld from or voted against at least one nominee.

43 vote records from 23 filers. 0 of the 23 filers that marked the item either way voted against management.

100.0% for0.0% against0.0% against management23 filers
2

SECTION 14A SAY-ON-PAY VOTESIssuer

Advisory vote on executive pay (say-on-pay)

1 vote records from 1 filers. 0 of the 1 filers that marked the item either way voted against management.

100.0% for0.0% against0.0% against management1 filers100.0% for0.0% against0.0% against management16,429 reported shares
3

AUDIT-RELATEDIssuer

Audit-related items (auditor ratification)

43 vote records from 23 filers. 0 of the 23 filers that marked the item either way voted against management.

100.0% for0.0% against0.0% against management23 filers100.0% for0.0% against0.0% against management4,369,142 reported shares
4

COMPENSATIONIssuer

COMPENSATION: management items

Management items in this category are shown together; filers word and number them differently.

43 vote records from 23 filers. 4 of the 23 filers that marked the item either way voted against management.

82.6% for17.4% against17.4% against management23 filers76.9% for23.1% against23.1% against management4,369,142 reported shares, counted once per item in this group
5

CORPORATE GOVERNANCEIssuer

CORPORATE GOVERNANCE: management items

Management items in this category are shown together; filers word and number them differently.

43 vote records from 23 filers. 6 of the 23 filers that marked the item either way voted against management.

73.9% for26.1% against26.1% against management23 filers75.9% for24.1% against24.1% against management4,369,142 reported shares, counted once per item in this group

How the largest families voted

Family1. Directors3. Auditor
VanguardForFor
BlackRock and iSharesForFor
FidelityForFor
DimensionalForFor
State Street and SPDRForFor
American CenturyForFor
Charles SchwabForFor
Nuveen and TIAAForFor
John Hancock and ManulifeForFor
Goldman SachsForFor
Jackson National fundsForFor
Lincoln FinancialForFor
Brighthouse FundsForFor
AllianceBernsteinForFor

* against management. A family's position is the way most of its reported shares were voted across its filers; "split" means no single position led. "No report" means none of the family's filers listed the item.

Questions

How did large funds vote at the Neuren Pharmaceuticals Limited meeting?

24 Form N-PX filers reported votes at the meeting of 27 May 2026. On say-on-pay, 0 of 1 voted against management (0.0%). The family table lists each of the largest families item by item.

Is this the meeting result?

No. These are the votes of funds and managers that file Form N-PX, counted by filer and by the shares they reported. The certified result, which includes every shareholder, is reported by Neuren Pharmaceuticals Limited on Form 8-K.

Why are director elections shown as counts only?

Director records name the nominee. This site does not publish pages or rows about individuals, so for director elections it keeps the number of nominees and the split of votes and discards the wording.

Every meeting on file for Neuren Pharmaceuticals Limited

Provenance: SEC EDGAR, Form N-PX and N-PX/A filings listing Neuren Pharmaceuticals Limited with a meeting date within three days of 27 May 2026. Proposal titles are the most common wording among filers and are replaced by the SEC category where a wording could name a person. Not verified by the SEC. Filings read through 23 Sep 2026.